Association of very deep prostate-specific antigen (PSA) decline with longer radiologic-progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer.

被引：0
|
作者：
Kapar, Caner
Tugcu, Volkan
Sahin, Selcuk
Guler, Haydar
Kilickap, Saadettin
Tural, Deniz
机构：
[1] Bakirkoy Res & Educ Hosp, Istanbul, Turkiye
[2] Istinye Univ, Dept Urol, Istanbul, Turkiye
[3] Bakirkoy Res & Educ Hosp, Dept Urol, Istanbul, Turkiye
[4] Kanuni Res & Educ Hosp, Dept Urol, Istanbul, Turkiye
[5] Istinye Univ, Fac Med, Dept Med Oncol, Istanbul, Turkiye
[6] Univ Hlth Sci, Dept Med Oncol, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17074
引用
收藏
页数：1
相关论文
共 50 条
  • [41] CLINICAL CHARACTERIZATION OF LOW PROSTATE-SPECIFIC ANTIGEN ON PROGNOSIS IN PATIENTS WITH METASTATIC CASTRATION-NAIVE PROSTATE CANCER
    Kodama, Hirotake
    Hatakeyama, Shingo
    Hoshi, Senji
    Kawaguchi, Tosiaki
    Ishidoya, Shigeto
    Shimoda, Jiro
    Mitsuzuka, Koji
    Tsuchiya, Norihiko
    Arai, Yoichi
    Habuchi, Tomonori
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2020, 203 : E953 - E953
  • [42] Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer
    Kodama, Hirotake
    Hatakeyama, Shingo
    Narita, Shintaro
    Takahashi, Masahiro
    Sakurai, Toshihiko
    Kawamura, Sadafumi
    Hoshi, Senji
    Ishida, Masanori
    Kawaguchi, Toshiaki
    Ishidoya, Shigeto
    Shimoda, Jiro
    Narita, Takuma
    Sato, Hiromi
    Mitsuzuka, Koji
    Tochigi, Tatsuo
    Tsuchiya, Norihiko
    Arai, Yoichi
    Habuchi, Tomonori
    Ohyama, Chikara
    CLINICAL GENITOURINARY CANCER, 2019, 17 (06) : E1091 - E1098
  • [43] Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting
    Sayegh, Nicolas
    Tripathi, Nishita
    Nussenzveig, Roberto H.
    Thomas, Vinay Mathew
    Tandar, Clara
    Goel, Divyam
    Nordblad, Blake
    Sahu, Kamal Kant
    Li, Haoran
    Maughan, Benjamin L.
    Agarwal, Neeraj
    Swami, Umang
    EUROPEAN UROLOGY FOCUS, 2023, 9 (01): : 106 - 109
  • [44] ASSOCIATION OF PROSTATE-SPECIFIC ANTIGEN TRAJECTORIES WITH MORTALITY IN VETERANS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Freedland, Stephen
    Young-Xu, Yinong
    Li, Sophia
    Pilon, Dominic
    Bhak, Rachel
    Duchesneau, Emilie
    Hellstern, Michael
    Behl, Ajay
    Lefebvre, Patrick
    Fuld, Alexander
    JOURNAL OF UROLOGY, 2019, 201 (04): : E497 - E498
  • [45] Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer
    Briones, Juan
    Khan, Maira
    Sidhu, Amanjot K.
    Zhang, Liying
    Smoragiewicz, Martin
    Emmenegger, Urban
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] PROSTATE-SPECIFIC ANTIGEN RESPONSE AND TIME-TO-CASTRATION RESISTANCE AMONG PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER INITIATED ON APALUTAMIDE, ENZALUTAMIDE, OR ABIRATERONE ACETATE
    Lowentritt, Benjamin
    Du, Shawn
    Rossi, Carmine
    Kinkead, Frederic
    Waters, Dexter
    Moore, Bronwyn
    Lefebvre, Patrick
    Pilon, Dominic
    Muser, Erik
    JOURNAL OF UROLOGY, 2023, 209 : E387 - E387
  • [47] Prognostic associations of early prostate-specific antigen (PSA) changes in patients with metastatic castration-resistant prostate cancer treated with with abiraterone acetate or enzalutamide
    Lopez Campos, F.
    Moreno, I.
    Conde-Moreno, A.
    Gomez-Iturriaga, A.
    Ruiz Vico, M.
    Romero Laorden, N.
    Henriquez Lopez, I.
    Peleteiro Higuero, P.
    Lozano Mejorada, R.
    Piquer, T.
    Couselo, M.
    Gomez Ramos, J.
    Navarro, J.
    Barrionuevo Castillo, P.
    Garcia, R.
    Villatoro, R.
    Montesa, A.
    Saez, M. I.
    Herrera, B.
    Castro Marcos, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 285 - 285
  • [48] Comparison of prostate-specific antigen (PSA) response in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) vs abiraterone acetate (ABI): A real-world (RW) causal analysis
    Brown, Gordon Andrew
    Du, Shawn
    Khilfeh, Ibrahim
    Rossi, Carmine
    Diaz, Lilian
    Kinkead, Frederic
    Lefebvre, Patrick
    Pilon, Dominic
    Ellis, Lorie
    Lowentritt, Benjamin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC)
    Armstrong, A. J.
    Eisenberger, M. A.
    Garrett-Mayer, E. S.
    Yang, Y. Ou
    Carducci, M. A.
    de Wit, R.
    Tannock, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
    Myint, Zin W.
    Kolesar, Jill M.
    McCorkle, Joseph Robert
    Wu, Jianrong
    Ellis, Carleton S.
    Otto, Danielle E.
    Wang, Peng
    MEDICAL SCIENCE MONITOR, 2022, 28
12345